Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Mechanical stiffness controls dendritic cell metabolism and function
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Musculoskeletal research protocols typically inject locally (within 12 cm of the target tissue) once or twice daily
Discover a sanctuary where beauty meets wellness, tailored to your unique lifestyle
PubMed CrossRef Lincoff AM, Brown-Frandsen K, Colhoun HM, et al
Rapid and comprehensive metabolites identification of 5-demethylnobiletin in rats using UPLC/Triple-TOF-MS/MS based on multiple mass defect filter and their neuroprotection against ferroptosis
US$ 25.19
US$ 23.70
US$ 20.86
US$ 28.46
US$ 27.70
US$ 29.35
US$ 22.05
